Levothyroxine supplementation for obesity-associated thyroid dysfunction in children: a prospective, randomized, case control study

Sugantha Kumar; Devi Dayal; Savita Attri; Atul Gupta; Anil Bhalla

doi:10.5114/pedm.2019.87709

eISSN: 2083-8441
ISSN: 2081-237X

Pediatric Endocrinology Diabetes and Metabolism

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

Journal integrated with

3/2019
vol. 25

Send email

Copy url:

abstract:

Original paper

Levothyroxine supplementation for obesity-associated thyroid dysfunction in children: a prospective, randomized, case control study

Sugantha Kumar

¹

,

Devi Dayal

¹

,

Savita Verma Attri

¹

,

Atul Gupta

¹

,

Anil Kumar Bhalla

¹

Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Pediatr Endocrinol Diabetes Metab 2019; 25 (3): 107-113

DOI: https://doi.org/10.5114/pedm.2019.87709

Online publish date: 2019/09/24

View full text Get citation

PlumX metrics:

Introduction
The specific treatment of thyroid dysfunction associated with simple obesity (SO) in children is controversial.

Material and methods
Fifty-one children having SO (BMI ≥ 2 Z-score) aged 6–12 years with elevation of serum thyroid stimulating hormone (TSH) (4–10 mIU/l) with or without alterations in serum triiodothyronine (T3) or thyroxine (T4) were randomised to receive either routine weight management intervention (group 1, n = 25) or additional low dose levothyroxine (~0.5 µg/kg/day) (group 2, n = 26) and followed up at 3-month intervals for 6 months.

Results
The mean BMI Z-scores decreased in both groups from baseline to 3 and 6-month time points (group 1, 3.69 ±1.31 to 3.24 ±1.45 to 2.84 ±1.46, p = 0.03 and group 2, 4.31 ±2.11 to 4.08 ±1.92 to 3.50 ±1.93, p = 0.02). However, the decrease was similar in the 2 groups (–0.80 ±0.77 vs –0.97 ±0.69, p = 0.19). All children had isolated hyperthyrotropinemia. The mean TSH levels decreased from baseline to endpoint in group 1 (5.51 ±1.0 to 4.14 ±1.0 to 4.04 ±1.1 mIU/l, mean change –1.44 ±1.20, p = 0.001) and in group 2 (5.89 ±1.10 to 5.89 ±1.10 to 3.89 ±1.48 mIU/l, mean change –1.93 ±1.15, p = 0.001). The decrease in TSH levels was also similar in the 2 groups (p = 0.69). TSH normalized in 48% and 57.6% in group 1 and group 2 respectively. The decrease in total cholesterol and triglyc-erides was also similar in the 2 groups.

Conclusions
Addition of levothyroxine to weight management interventions has no beneficial effect on BMI reduction as well as parameters of lipid and thyroid profiles, and should not be prescribed to children with obesity associated thyroid dysfunction.

keywords:

Levothyroxine supplementation for obesity-associated thyroid dysfunction in children: a prospective, randomized, case control study

Sugantha Kumar 1 , Devi Dayal 1 , Savita Verma Attri 1 , Atul Gupta 1 , Anil Kumar Bhalla 1

exogenous obesity, obesity associated thyroid dysfunction, isolated hyperthyrotropinemia, subclinical hypothyroidism, levothyroxine, children

Sugantha Kumar

¹

,

Devi Dayal

¹

,

Savita Verma Attri

¹

,

Atul Gupta

¹

,

Anil Kumar Bhalla

¹